Anteris To Present At September Healthcare Investor Conferences
| Date: | Wednesday, September 9, 2026 (US time) |
| Format: | Fireside chat with analyst, Gabie Ingoglia, and 1x1 meetings |
| Time: | 11:30AM (US EST) |
| Room: | Track 1 – Metropolitan Room |
| Location: | Waldorf Astoria Hotel, New York |
Wells Fargo Healthcare Conference
| Date: | Thursday, September 10, 2026 (US time) |
| Format: | Fireside chat with analyst, Larry Biegelsen, and 1x1 meetings |
| Time: | 9:30AM (US EST) |
| Room: | Track 1 – Picasso 6 |
| Location: | Encore Boston Harbor Hotel, Boston |
Morgan Stanley Healthcare Conference
| Date: | Monday, September 14, 2026 (US time) |
| Format: | Fireside chat with Morgan Stanley Healthcare Team |
| Time: | 9:15AM (US EST) |
| Room: | Soho Complex 7th Floor |
| Location: | Sheraton Times Square Hotel, New York |
About Anteris
Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) is a global healthcare company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Founded in Australia, with a significant presence in Minneapolis, USA, Anteris is a science-driven company with an experienced team of multidisciplinary professionals delivering restorative solutions to structural heart disease patients.
Anteris' lead product, the DurAVR® Transcatheter Heart Valve (THV), was designed in collaboration with the world's leading interventional cardiologists and cardiac surgeons to treat aortic stenosis – a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR® THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. DurAVR®THV is made using a single piece of molded ADAPT® tissue, Anteris' patented anti-calcification tissue technology. ADAPT® tissue, which is FDA-cleared, has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide. The DurAVR® THV System is comprised of the DurAVR® valve, the ADAPT® tissue, and the balloon-expandable ComASUR® Delivery System.
Forward-Looking Statements
This announcement contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. Forward-looking statements generally are identified by the words“believe,”“project,”“expect,”“anticipate,”“estimate,”“intend,”“budget,”“target,”“aim,”“strategy,”“plan,”“guidance,”“outlook,”“may,”“should,”“could,”“will,”“would,”“will be,”“will continue,”“will likely result” and similar expressions, although not all forward-looking statements contain these identifying words. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions, including those described under“Risk Factors” in Anteris' Annual Report on Form 10-K for the fiscal period ended December 31, 2025 that was filed with the Securities and Exchange Commission and ASX. Actual future events may vary from these forward-looking statements and readers are cautioned not to put undue reliance on forward-looking statements. Other than as required by law, Anteris gives no representation or guarantee that the occurrence of any of the events or circumstances expressed or implied in these statements will occur. In addition, except as required by law, Anteris does not assume any obligation to update any of these forward-looking statements to conform these statements to actual results or revised expectations.
For more information:
| Global Investor Relations ... Debbie Ormsby Anteris Technologies Global Corp. +61 1300 550 310 | +61 7 3152 3200 | Investor Relations (US) ... Malini Chatterjee, Ph.D. Blueprint Life Science Group +1 917 330 4269 | |
| Website X | @AnterisTech |
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.
Comments
No comment